StreetInsider.com News Articles

Form 8-K Bausch & Lomb Corp For: Oct 11

Tue, 13 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261013/27176400.html

Form 8-K Bausch & Lomb Corp For: Oct 11

Tue, 13 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261013/27176400.html

Bausch + Lomb names Appio interim CEO as Saunders departs

Mon, 12 Oct 2026 06:46:08 -0400

Bausch + Lomb Corporation (NYSE: BLCO) has appointed Thomas J. Appio as interim chief executive officer, effective immediately, following the mutual departure of Brent Saunders, who had served as CEO since 2023, according to a press release from the company and its parent, Bausch Health Companies Inc. (NYSE/TSX: BHC).

Appio, who has served as CEO of Bausch Health since 2022 and was appointed chairman of the Bausch + Lomb board in August 2026, will hold both roles simultaneously. He joined Bausch + Lomb in 2010 as managing director for China and became president of Bausch + Lomb International in 2016.

During Appio's

Bausch + Lomb names Appio interim CEO as Saunders departs

Mon, 12 Oct 2026 06:46:08 -0400

During Appio's

Bausch + Lomb names Appio interim CEO as Saunders departs

Mon, 12 Oct 2026 06:46:08 -0400

During Appio's

Bausch + Lomb names Appio interim CEO as Saunders departs

Mon, 12 Oct 2026 06:46:08 -0400

During Appio's

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb.

Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio’s deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Mon, 12 Oct 2026 06:45:00 -0400

RBC Capital on Bausch & Lomb Corp. (BLCO): 'Rx DED momentum drives estimates higher'

Thu, 08 Oct 2026 08:04:20 -0400

RBC Capital analyst Douglas Miehm reiterated an Outperform rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).

The analyst commented: "Rx DED momentum drives estimates higher; FX turned into a slight headwind; BLCO will report Q3/26 results on October 28 (bmo). We estimate Q3/26 revenue of $1,375MM (cons. $1,371MM) and adj. EBITDA of $275MM (cons. $272MM), with $4MM in FX-driven revenue headwinds. Key areas of investor focus include: the DED Rx franchise (Miebo has achieved #1 U.S. branded Rx DED drug status); key near-term launches (Elios MIGS approval/launch timing, enVista Beyond submission, seeLyra EU rollout); the FDA Warning

Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

Tue, 06 Oct 2026 16:30:21 -0400

Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a meeting with the U.S. Food and Drug Administration (FDA).

According to a company press release, the FDA was supportive in principle of the proposed initial study design, which will evaluate how the medicine behaves in the body and assess its safety. Results from that initial study are expected, barring unexpected findings, to support advancement into a Phase 2 study in patients with dry AMD who have not yet developed advanced retinal damage. Bausch + Lomb

Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

Tue, 06 Oct 2026 16:30:21 -0400

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Tue, 06 Oct 2026 16:30:00 -0400

BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited
Clinical development program expected to begin in 2027

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA).